Gastrointestinal cancer

OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
Wednesday, March 20, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Research, Multiple myeloma, Lung cancer, Partner, NMPA, Growth, NSCLC, CIDP, Partnership, Telephone, GSK, Patient, TED, NASDAQ Biotechnology Index, Epitope, Artificial intelligence, Sale, Myasthenia gravis, Neonatal Fc receptor, Fluorouracil, Graves' ophthalmopathy, Investment, Teclistamab, NBI, National Medical Products Administration, Johnson & Johnson, Drug development, Safety, Chicken, Machine learning, Gastrointestinal cancer, Immunoglobulin G, BLA, Chronic inflammatory demyelinating polyneuropathy, Pharmaceutical industry

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2023, and provided operating and partner program updates.
  • OmniAb launched two new technologies during 2023 including OmniDeep™ and, during the fourth quarter, OmnidAb™.
  • Fourth quarter 2023 and recent partner highlights include the following:
    Immunovant reported positive initial results for batoclimab in Graves’ disease (GD).
  • OmniAb was added to the Nasdaq Biotechnology Index (NBI) in the fourth quarter.

Debbie's Dream Foundation: Curing Stomach Cancer Announce Groundbreaking Research Fellowship Grant for Gastric Cancer Research

Retrieved on: 
Tuesday, March 19, 2024
Partnership, Education, Patient, Biomarker, Research, Helicobacter pylori, AACR, DRS, DDF, Stomach, MSK, Gastrointestinal cancer, Health, Stomach cancer, Pharmaceutical industry

FORT LAUDERDALE, Fla., March 19, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) announces an unprecedented collaboration with Memorial Sloan Kettering Cancer Center (MSK) that marks a significant leap forward in the field of gastric cancer research. Through the visionary efforts and support of DDF, a research fellowship grant has been established at MSK under the guidance of Dr. Yelena Janjigian, Chief of Gastrointestinal Oncology Service at MSK. The "Debbie's Dream Foundation Gastric Cancer Investigator" fellowship will focus on patient care, research, and education specifically for esophageal and gastric cancers. The collaboration is a testament to the shared commitment of DDF and MSK to fueling groundbreaking research and providing top-notch cancer care.

Key Points: 
  • FORT LAUDERDALE, Fla., March 19, 2024 /PRNewswire/ -- Debbie's Dream Foundation: Curing Stomach Cancer (DDF) announces an unprecedented collaboration with Memorial Sloan Kettering Cancer Center (MSK) that marks a significant leap forward in the field of gastric cancer research.
  • The "Debbie's Dream Foundation Gastric Cancer Investigator" fellowship will focus on patient care, research, and education specifically for esophageal and gastric cancers.
  • The collaboration is a testament to the shared commitment of DDF and MSK to fueling groundbreaking research and providing top-notch cancer care.
  • Through the 'Debbie's Dream Foundation Gastric Cancer Investigator fellowship, we aim to make impactful strides in biomarker development, laboratory research, and translational studies in gastroesophageal cancer."

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

Retrieved on: 
Thursday, March 7, 2024
SAN, Neoplasm, Division, Research fellow, Immunotherapy, Colorectal cancer, Gastrointestinal cancer, Drug development, Mentorship, Clinical research, Pembrolizumab, CRC, MSS, National Cancer Institute, FACP, Preventive healthcare, Gene expression, NCCN, USC, Associate, Patient, Harvard Medical School, Oncology, George Washington University, Cancer, Pharmaceutical industry

SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the “SAB”).

Key Points: 
  • SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the “SAB”).
  • Dr. Lenz accelerates translational and clinical research and provides training and mentoring in the design and implementation of investigator-initiated trials.
  • In 1991, he completed his internship, residency, and fellowship training at the Eberhardt Karls Universität in Tübingen, Germany.
  • “His insight and clinical experience as a leading expert in colorectal cancer is of great importance as we develop our SAFEbody® ADG126 for patients worldwide.”
    For more information about members of the Adagene Scientific and Strategic Advisory Board, visit: https://www.adagene.com/about/key-advisors/

Inflammatory Bowel Disease Expert and Harvard Medical School Faculty Dr. Hamed Khalili Joins Vivante Health’s Clinical Advisory Board

Retrieved on: 
Monday, February 26, 2024
Research, American Gastroenterological Association, Inflammatory Bowel Diseases, Education, Colorectal cancer, Physician, Quality of life, Hospital, Epidemiology, Gastrointestinal cancer, Vivante Corporation, American College, Inflammatory bowel disease, Associate, Massachusetts General Hospital, Harvard Medical School, Stanford University Medical Center, State, Nursing

CHICAGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Vivante Health , the employee benefit for GI care, announced the addition of Dr. Hamed Khalili to its Clinical Advisory Board today.

Key Points: 
  • CHICAGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Vivante Health , the employee benefit for GI care, announced the addition of Dr. Hamed Khalili to its Clinical Advisory Board today.
  • Dr. Khalili is a gastroenterologist and Director of Clinical Research at Massachusetts General Hospital, Crohn’s and Colitis Center and an Associate Professor at Harvard Medical School.
  • His research focuses on studying dietary and lifestyle factors and their relationship to the development and progression of inflammatory bowel diseases.
  • “Vivante Health is doing fantastic work to care for people with digestive conditions, particularly in the area of inflammatory bowel disease and other digestive conditions.

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Retrieved on: 
Thursday, March 7, 2024
Neoplasm, Research, Toxicity, SCCA, FOLFIRINOX, Trifluridine/tipiracil, PR, Society, Breast, Health, Poster, Immunotherapy, Anal cancer, Pancreatic cancer, Fast Track, Anal, Progression-free survival, SITC, Pelareorep, Annual general meeting, Congress, Cancer, Gastrointestinal cancer, AB, International, Cohort, ESMO, Conference, Safety, TILS, Tumor microenvironment, Clinical trial, Survival, MOA, Oncology, Colorectal cancer, TIL, Blood, FDA, TSX, Thought, Pancreatic Cancer Action Network, Anal canal, PDAC, Patient, ONC, Pharmaceutical industry

ET

Key Points: 
  • ET
    SAN DIEGO and CALGARY, AB, March 7, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced recent operational highlights and financial results for the fourth quarter and year ended December 31, 2023.
  • General and administrative expenses for the fourth quarter of 2023 were $4.2 million, compared to $3.7 million for the fourth quarter of 2022.
  • Research and development expenses for the fourth quarter of 2023 were $4.7 million, compared to $4.8 million for the fourth quarter of 2022.
  • The net loss for the fourth quarter of 2023 was $3.9 million, compared to a net loss of $8.6 million for the fourth quarter of 2022.

First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab

Retrieved on: 
Wednesday, February 14, 2024
Gastrointestinal cancer, Cancer, GEJ, Mink, Stomach, GI, Therapy, Paclitaxel, Patient, Disease, Tissue, Pharmaceutical industry

The trial builds upon findings from MiNK’s recently published clinical trial ( Carneiro et al .

Key Points: 
  • The trial builds upon findings from MiNK’s recently published clinical trial ( Carneiro et al .
  • 2024 Oncogene) demonstrating that agenT-797 appears to overcome resistance to immune checkpoint inhibitors, with durable disease stabilization and a confirmed response in chemotherapy and anti-PD-1 refractory gastric cancer.
  • "AgenT-797, an off-the-shelf iNKT cell-based therapy, has shown the capacity to target cancerous cells in diseased tissues and is compatible with immune checkpoint inhibitors.
  • This study builds upon the promising outcomes observed with iNKTs in gastric cancer and with botensilimab/balstilimab in GI cancers.

RenovoRx CEO Issues Letter to Shareholders

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Standard of care, LAPC, Pancreatic cancer, IMU, Patient, New Drug Application, FDA, Death, TAMP, Patent Cooperation Treaty, Cancer, Patent, Letter, ASX, Gastrointestinal cancer, System, Pharmaceutical industry

(“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from Chief Executive Officer, Shaun Bagai.

Key Points: 
  • (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from Chief Executive Officer, Shaun Bagai.
  • 2023 was a pivotal year for RenovoRx, and we believe our accomplishments bode well for the achievement of our anticipated 2024 milestones.
  • TIGeR-PaC is an ongoing Phase III randomized multi-center study evaluating our lead product candidate, RenovoGem™ for the treatment of LAPC.
  • RenovoGem is a novel oncology drug-device combination product utilizing our TAMP administration technology combined with the FDA-approved cancer drug, gemcitabine.

Agilis Robotics Unveils Groundbreaking Advancements in Endoluminal Surgery

Retrieved on: 
Monday, February 5, 2024
Multimedia, Surgeon, Cystoscopy, Robotics, University, CFO, Chapter, System, Patient, Safety, National Medical Products Administration, FDA, Food, NMPA, University of Hong Kong, Food and Drug Administration, Bladder cancer, Learning curve, Gastrointestinal cancer, HKEX, Hospital, Pharmaceutical industry

HONG KONG, Feb. 2, 2024 /PRNewswire/ -- Agilis Robotics, a leading innovator in surgical robotics, is spearheading a paradigm shift in the field of "incisionless" endoluminal surgery.

Key Points: 
  • HONG KONG, Feb. 2, 2024 /PRNewswire/ -- Agilis Robotics, a leading innovator in surgical robotics, is spearheading a paradigm shift in the field of "incisionless" endoluminal surgery.
  • The robotic instruments offer unprecedented possibilities across endoluminal surgery, spanning the upper and lower gastrointestinal (GI) tract, urinary tract, throat, and gynaecology.
  • Agilis Robotics is a spin-off from The University of Hong Kong and has secured more than HKD 90 million in funding from private investors.
  • Furthermore, Agilis Robotics understands the importance of cost-effectiveness, marketability, and market potential, ensuring a successful venture for investors and hospitals.

Gilead and Arcus Announce Amended Collaboration and Equity Investment

Retrieved on: 
Monday, January 29, 2024
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Pancreatic cancer, Patient, Research, MD, Science, Partnership, Cancer, Lung cancer, NSCLC, CD73, Gilead Sciences, Safety, Gastrointestinal cancer, Doctor of Philosophy, TIGIT, Lung, Kidney cancer, Growth, Pharmaceutical industry

Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share.

Key Points: 
  • Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced an amendment to their collaboration agreement and a separate equity investment by Gilead of $320 million in Arcus common stock at $21.00 per share.
  • The equity investment and collaboration amendment enable accelerated growth of the companies’ joint development programs that span multiple indications.
  • Additionally, Johanna Mercier, Chief Commercial Officer at Gilead Sciences, will join the Arcus Board, bringing Gilead’s total director designees to three.
  • The amendment also includes governance enhancements enabling streamlined decision-making and reflecting the continued growth of the collaboration.

RenovoRx Closes $6.1 Million Private Placement

Retrieved on: 
Monday, January 29, 2024
Biotechnology, FDA, Professional Services, Health, Pharmaceutical, Oncology, Medical Devices, Research, Science, Clinical Trials, Finance, Death, Pancreatic cancer, Patient, Cancer, TAMP, Sarcoma, Glioblastoma, DMC, Standard of care, Cougar, Data monitoring committee, Cholangiocarcinoma, Sale, Lung cancer, LAPC, Investment, Phase, Clinical trial, Gastrointestinal cancer, Pharmaceutical industry

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that it has closed a private placement (the “private placement” or the “financing”) resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses.

Key Points: 
  • RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that it has closed a private placement (the “private placement” or the “financing”) resulting in gross proceeds of approximately $6.1 million, before deducting offering expenses.
  • RenovoRx insiders, including members of the management team and Board of Directors, participated in the private placement.
  • The warrants are exercisable at a price equal to the per share price paid by the applicable investor and are exercisable for a period of five years following the closing of the private placement.
  • “I have now chosen to join as an investor in this private placement financing.